To determine the overall survival of patients with metastatic cancer through evaluating labortory, clinical and pathological investigations.
Not Applicable
- Conditions
- Health Condition 1: null- Metastatic breast cancer OR Recurrent ovarian cancer ORGastric/Gall bladder/Pancreatic cancer
- Registration Number
- CTRI/2017/04/008402
- Lead Sponsor
- Tata Memorial Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Closed to Recruitment of Participants
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Metastatic breast cancer who have received at least 2 lines of chemotherapy in metastatic setting and progressed thereafter
OR
2. Recurrent ovarian cancer who have received at least 2 lines of chemotherapy for recurrent disease and progressed therafter
OR
3. Gastric/Gall bladder/Pancreatic cancer patients who have received at least 1 line of chemotherapy and progressed thereafter
Exclusion Criteria
Not willing to consent for participation or not willing to be followed-up.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. To determine the association of overall survival with various clinical, laboratory and pathological factors in patients with advanced metastatic solid cancers. <br/ ><br>2. To create a model for predicting survival using significant variables. <br/ ><br>3. To use the model to predict survival estimates in an independent validatory set of patients.Timepoint: Patients, satisfying the inclusion criteria and willing to participate in the study, would be recruited and prospectively followed up every 3 months (physically /telephonically) over a period of 24 months from the date of visit.
- Secondary Outcome Measures
Name Time Method To build a model, using commonly available clinical, pathologic and laboratory variables, to predict survival in patients with advanced solid cancers.Timepoint: 24 months from the date of visit.